

Tnni1b-ECR183-d2, an 87 bp cardiac enhancer of zebrafish

Yawen Zhang^{1,2,*}, Feng Wang^{1,2,*}, Fang Wu^{1,2}, Youhua Wang³, Xu Wang⁴, Yonghao Gui² and Qiang Li¹

¹Translational Medical Center for Development and Disease, Shanghai Key Laboratory of Birth Defect, Institute of Pediatrics, Children's Hospital of Fudan University, Shanghai, China

²Department of Cardiology, Children's Hospital of Fudan University, Shanghai, China

³Department of Cardiology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

⁴Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China

*These authors contributed equally to this work.

ABSTRACT

Background. Several heart malformations are associated with mutations in the regulatory regions of cardiac genes. *Troponin I type 1b* (*tnni1b*) is important for the formation of the atrioventricular canal in zebrafish hearts; however, the regulation of *tnni1b* is poorly understood. We aimed to identify a small but functional enhancer that is distal to *tnni1b*.

Methods. Evolutionary Conserved Region (ECR) Browser was used to analyze the 219 kb zebrafish and human genomes covering the *tnni1b* gene as well as the 100 kb regions upstream and downstream of *tnni1b*. Putative transcription factor binding sites (TFBSs) were analyzed using JASPAR and PROMO, and the enhancer activity was identified using zebrafish embryos and the luciferase reporter assay. A correlation analysis between the enhancer and transcription factors (TFs) was performed via TF overexpression and TFBS mutation experiments and the electrophoretic mobility shift assay (EMSA). To analyze the conservation between zebrafish and human enhancers, human DNA fragments were functionally verified. Images were captured and analyzed by fluorescence microscopy or confocal microscopy.

Results. Combined with comparative analysis and functional validation, we identified a 183 bp ECR (termed tnni1b-ECR183) that was located approximately 84 kb upstream of *tnni1b* that had the heart-specific enhancer activity in zebrafish. TFBS analysis and the enhancer activity detection assay data showed that the 87 bp core region (termed tnni1b-ECR183-d2) was capable of driving specific GFP expression near the atrioventricular junction and increased luciferase expression in HEK293 and HL1 cell lines. The GFP pattern in zebrafish embryos was similar to the expression profiles of *tnni1b*. A correlation analysis showed that the enhancer activity of tnni1b-ECR183-d2 was increased when NKX2.5 ($p = 0.0006$) or JUN ($p < 0.0001$) was overexpressed and was decreased when the TFBSs of NKX2.5 ($p < 0.0001$) or JUN ($p = 0.0018$) were mutated. In addition, DNA-protein interactions were not observed between these TFs and tnni1b-ECR183-d2 in the EMSA experiment. The conservation analysis showed that tnni1b-ECR183-h179 (aligned from tnni1b-ECR183) drove GFP expression in the heart and skeletal muscles and increased the luciferase expression after NKX2.5 ($p < 0.0001$), JUN ($p < 0.0001$) or ETS1 ($p < 0.0001$) was overexpressed. Interestingly, the truncated fragment tnni1b-ECR183-h84 mainly drove GFP expression in the skeletal

Submitted 19 December 2019

Accepted 12 October 2020

Published 4 November 2020

Corresponding authors

Yonghao Gui, yhgui@fudan.edu.cn

Qiang Li, liq@fudan.edu.cn

Academic editor

Mason Posner

Additional Information and
Declarations can be found on
page 18

DOI 10.7717/peerj.10289

© Copyright

2020 Zhang et al.

Distributed under

Creative Commons CC-BY 4.0

OPEN ACCESS

muscles of zebrafish and the enhancer activity decreased when NKX2.5 ($p = 0.0028$), ETS1 ($p = 0.0001$) or GATA4 ($p < 0.0001$) was overexpressed.

Conclusions. An 87 bp cardiac-specific enhancer located 84 kb upstream of *tnni1b* in zebrafish was positively correlated with NKX2.5 or JUN. The zebrafish and human enhancers in this study target different tissues. The GFP expression mediated by *tnni1b*-ECR183-d2 is a valuable tool for marking the domain around the atrioventricular junction.

Subjects Developmental Biology, Genetics, Molecular Biology, Cardiology, Pediatrics

Keywords Evolutionary conserved region, *Tnni1b*, Cis-regulators, Transgenic zebrafish line, Transcription factor

INTRODUCTION

Congenital heart disease (CHD) is one of the most common birth defects and is associated with genetic factors, environmental factors, or both (*Van der Bom et al., 2012; Fahed et al., 2013*). The genetic factors, such as mutations of cardiac genes, can lead to abnormal embryonic heart development. In 2015, a large cohort study published in Science reported that either a single gene mutation or multiple gene mutations contributed to CHD pathogenesis (*Homsy et al., 2015; Zhang, Liu & Tian, 2019*). Notably, functional regulatory elements including promoters, enhancers and silencers, are necessary to regulate the temporal and spatial expression of target genes (*Waardenberg et al., 2014; Postma, Bezzina & Christoffels, 2016*), indicating that variations in regulatory regions might explain the cause of CHDs with no mutations in the coding regions. Studies of regulatory regions are mostly focused on promoter regions, which are generally located approximately 2 kb upstream of genes. Notably, several long-range regulatory elements are also functional, such as a functional enhancer that has been identified to lie within 1 Mb of the target gene *Shh* (*Lettice et al., 2003*). The previously reported gene-related enhancers are mostly hundreds to thousands of base pairs in length (*Abbasi et al., 2010; Anwar et al., 2015*). Interestingly, researchers also found that some enhancers are small, such as a 187 bp dorsal midline-specific enhancer and a 44 bp vit-2 enhancer (*Charité et al., 2001; Kim, Park & Park, 2015; Goszczynski et al., 2016*). These studies suggest that some distant and small enhancers are still capable of regulating gene expression.

Comparative genomics analysis is one of the most important methods to screen for functional regulatory elements. The ECR Browser (<http://ecrbrowser.dcode.org>) provides dynamic access to whole-genome sequences of different species, and it has been widely used to locate the regulatory elements because of its many advantages, including speed, high sensitivity and ease of operation (*Ovcharenko et al., 2004; Delporte et al., 2008; Ikle, Artinger & Clouthier, 2012; Anwar et al., 2015; Sun, Chen & Peng, 2015*). Moreover, the zebrafish is a valuable model organism for the identification and functional analysis of regulatory element activity (*Taminato et al., 2016; Posner et al., 2017; Chan et al., 2019*). Some fluorescently-labeled transgenic zebrafish lines have been widely used in clinical and

scientific research (Hernández-Vega & Minguillón, 2011; Arkhipova et al., 2012; Suarez-Bregua et al., 2017). In other words, some important regulatory elements can be identified by comparative genomics analysis and functional verification in zebrafish, and one such fluorescently labeled transgenic zebrafish line will be useful for relevant researches.

Previously, researchers found that *tnni1b*^{-/-} zebrafish embryos had several cardiac developmental abnormalities, including severe pericardial edema, heart tube deformities, endocardial ring deficiency and valve leaflet abnormalities (Shih et al., 2015; Cai et al., 2019). Data from the Gene Cards database (<https://www.genecards.org/>) show that the homology between zebrafish *tnni1b* and human TNNI1 is approximately 74.73(n) (Sheng & Jin, 2016), and the RNA-seq data revealed a high expression level of *tnni1b* in the zebrafish heart. Accordingly, it is essential to study the appropriate expression of *tnni1b* to enhance our understanding of the relationship between *tnni1b* and heart development. Currently, there are few studies on the regulatory network of *tnni1b*.

Therefore, in this study, a comparative analysis and functional validation were combined to investigate the functional enhancers of *tnni1b*. We successfully screened a long-range enhancer that was small but still capable of driving the specific GFP expression near the atrioventricular junction of the zebrafish heart. Considering that the enhancer in our study is small and specific, the reporter gene expression in zebrafish driven by this enhancer is a valuable tool for marking the domain around the atrioventricular junction, which means that the related transgenic zebrafish line is helpful for cardiovascular research.

MATERIALS AND METHODS

Comparative analysis of the genomic loci of *tnni1b*

Evolutionary Conserved Region (ECR) Browser (<http://ecrbrowser.dcode.org/>) was used to screen for ECRs and perform genome alignment. The zebrafish (zv9) genome was set as the base genome and compared with the human (hg19) genome. To locate the functional regulatory elements, a 219 kb genomic range covering the *tnni1b* gene and 100 kb regions upstream and downstream of *tnni1b* were analyzed. Furthermore, we set the ECR length parameter to be greater than 100 bp and the similarity between human and zebrafish genomes to be above 70%. ECRs with transposons and simple repeats were excluded in this study.

Analysis of the putative TFBSs

Databases including JASPAR (<http://jaspar.genereg.net/>) and PROMO (http://algggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) were used to seek and to analyze the putative TFBSs of the enhancer sequence. As previously reported (Sandelin et al., 2004), the species was selected, and the relative profile score threshold was set to 80% to scan the target DNA sequence. Among the putative transcription factors (TFs), cardiac TFs were selected to study the correlation between them and the enhancer in our study. The regions that were covered by the most putative TFBSs were thought to be the potential core region corresponding to the original enhancer sequence.




Figure 1 Diagrams of enhancer activity detection constructs in this study. (A) Enhancer activity detection construct used for microinjection. (B) Enhancer activity detection construct used for the luciferase reporter assay.

Full-size DOI: 10.7717/peerj.10289/fig-1

Construction of the TF overexpression, enhancer activity detection and mutation analysis constructs

The ETS1 overexpression construct generated from the ETS1 cDNA sequence and the pcDNA3.1 vector was kindly provided by Professor G. Huang from the Children's Hospital of Fudan University. The cDNA sequences of NKX2.5 and JUN, which were cloned into the pENTER vector (Vigenebio, China), were synthesized by Shanghai Sunny Biotechnology Co., Ltd. The zebrafish and human DNA sequence of the enhancer was downloaded from the ECR Browser. DNA regions of the candidate enhancers were amplified by PCR, cut with XhoI and BglII and cloned into pCNE7.04-E1b-GFP-T2KXIGQ, the enhancer activity detection vector (*Li et al., 2010*) (Fig. 1A). To construct a luciferase reporter plasmid (Fig. 1B), enhancer fragments were cut with KpnI and XhoI, and the original SV40 promoter of the luciferase reporter vector pGL3-promoter (Promega; USA) was replaced by E1b, which is a widely used basic promoter. We termed this new vector pGL3-E1b. In the mutated enhancer constructs, a single base in the TFBSs was mutated but was not introduced a new heart-related TFBS. The primer sequences used for PCR amplification of the enhancer activity detection and mutation analysis constructs are listed in Table 1.

Zebrafish maintenance, microinjection, and transgenic line generation

The animal protocols were approved by the Institutional Animal Care and Use Committee of Children's Hospital of Fudan University (approval reference number: EK201873). Zebrafish strains used in this study included TU wild-type and transgenic line *Tg* (*myl7:mCherry*) (kindly provided by Professor Q. Jiang at Zhongshan Hospital of Fudan University), which was a transgenic line with cardiomyocyte-specific red fluorescence driven by the promoter of *myl7*. Embryos for fluorescence observation were incubated in blue egg water containing 0.003% phenylthiourea to inhibit pigmentation. In brief, a microinjection solution containing 25~50 ng/ μ l DNA from the candidate regulatory

Table 1 Primer sequences used for PCR amplification of the enhancer activity detection and TFBS mutation analysis constructs.

Constructs	Sequences (5'–3')
ptnni1b-ECR183-E1b- GFP-T2KXIGQ	F: agagctcgagctgacagatagctgctgccgtagag R: agagagatctgtctctttccctctgcagttgtctg
ptnni1b-ECR183-d1-E1b- GFP-T2KXIGQ	F: tcgagccaggagagaggagacgagcgggttgagaggctggagatgctcgagcattggttcatcgctgataa R: gatcttatgacagcagatgaaaccaatgctcgagcatctccagcctccaaccgctc gtctctctctctctggc
ptnni1b-ECR183-d2-E1b- GFP-T2KXIGQ	F: tcgagctgacagatagctgctgccgtagaggaaggagcatctccggctggagacgag- gactggactgacctggcgccaggagagaggaga R: gatctctctctctctggcgccacggctcagtcagtcctcgtctccaagccggagat gctcctctctaccggcagcagctatctgtcagc
ptnni1b-ECR183-d3-E1b- GFP-T2KXIGQ	F: tcgagtacagatagctgctgccgtagaggaaggagcatctccgga R: gatctccggagatgctctctctaccggcagcagctatctgtcac
ptnni1b-ECR183-h179-E1b- GFP-T2KXIGQ	F: agagctcgagccgagcggcagctcccaccacaga R: agagagatctgctctctctccaccagctccc
ptnni1b-ECR183-h84-E1b- GFP-T2KXIGQ	F: tcgagccgagcggcagctcccaccacagaggcgctcaccagcctgcagccg- gactggactggccatagcgcctgacagagggga R: gatctcccctctctctgagcctatggcagtcagtcggcggctgcagcggctgacgcgcctctgtgggtgggagctgccgctcggc
pGL3-E1b-tnni1b- ECR183	F: agagggtaccctgacagatagctgctgccgtagag R: agagctcgagtgctctttccctctgcagttgtctg
pGL3-E1b-tnni1b- ECR183-d2	F: cctgacagatagctgctgccgtagaggaaggagcatctccggctggagacgaggactggactgacctggcgccaggagagaggagc R: tcgagctctctctctctggcgccacggctcagtcagtcctcgtctccaagccggagat gctcctctctaccggcagcagctatct- gtcagggtac
pGL3-E1b-tnni1b- ECR183-h179	F: agagggtaccctgagcggcagctcccaccacaga R: agagctcgagtgctctctctccaccagctccc
pGL3-E1b-tnni1b- ECR183-h84	F: cccgagcggcagctcccaccacagaggcgctcaccagcctgcagccggactggactggccatagcgcctgacagagggggc R: tcgagccccctctctctgagcctatggcagtcagtcggcggctgcagcggctgta cgcgcctctgtgggtgggagctgc- cgctcgggtac
pGL3-E1b-tnni1b- ECR183-d2-NKX2.5-mut	F: cctgacagatagctgctgccgtagaggaaggagcatcg(t)ccggctggagacgaggactggactgacctggcgccaggagagaggagc R: tcgagctctctctctctggcgccacggctcagtcagtcctcgtctccaagccggc(a) gatgctctctctaccggcagcagctatct- gtcagggtac
pGL3-E1b-tnni1b- ECR183-d2-JUN-mut	F: cctgat(c)agatagctgctgccgtagaggaaggagcatctccggctggagacgaggactggagc(t)gacctggcgccaggagagaggagc R: tcgagctctctctctctggcgccacggctcc(a)gtccagtcctcgtccaagccggga gatgctctctctaccggcagcagc- tatcta(g)tagggtac

Notes.

F:Forward primer sequence.

R:Reverse primer sequence.

Mutant bases are shown as bolded text, original bases are in parentheses.

region, 25 ng/μl tol2 mRNA and 0.1% phenol red was injected into fertilized zebrafish embryos at the single cell stage. Approximately 50 embryos on average survived at 24 h post-fertilization (hpf). F0 fish with positive green fluorescent expression were outcrossed with TU wild-type fish to obtain the F1 generation, and the F2 generation was back-crossed offspring of F1. For the co-localization analysis, *Tg* (*myl7*: mCherry), which was labeled by red fluorescence specifically in cardiomyocytes, was crossed with the transgenic zebrafish line in this study.

Cell culture, transfection, and luciferase reporter assay

The HEK293 and HL1 cell lines were purchased from Shanghai Fuheng Biotechnology Co., Ltd. Cells were maintained in 60 mm tissue culture grade dishes at 37 °C in 5% CO₂. The culture medium was DMEM, high glucose, pyruvate (Cat. No. 11995065; Invitrogen; USA) supplemented with 10% fetal bovine serum (Cat. No. 10099141; Invitrogen; USA), 100 U/ml

penicillin (Invitrogen; USA) and 100 mg/ml streptomycin (Invitrogen; USA). HEK293 and HL1 cells were plated in 96-well plates at 5×10^3 cells/well and 8×10^3 cells/well, respectively. For the enhancer activity detection assay, both HEK293 and HL1 cells were transfected with a 100 ng/well enhancer activity detection construct using Lipofectamine 3000 reagent (Cat. No. L3000015; Invitrogen; USA) according to the manufacturer's instructions after 24 h of culture. For the TF overexpression experiment, both the enhancer activity detection construct (100 ng/well) and TF overexpression construct (100 ng/well) were cotransfected into HEK293 cells, while for the TFBS mutation experiment, only the enhancer mutation analysis construct (100 ng/well) was transfected. After 48 h of transfection, cells were collected to obtain the lysate, and the firefly and Renilla luciferases were detected by a Dual-luciferase Reporter Assay System (Cat. No. E1910; Promega; USA). The ratio of the firefly luciferase value and the *Renilla* luciferase value was the relative luciferase activity. Experiments were repeated for three times. For the EMSA experiment, HEK293 cells were maintained in 60 mm dishes. Cells were transfected when they reached 70% confluence. In total, 10 μ g TF overexpression construct was transfected into the cells, the cells were incubated for 48–72 h after transfection, and protein extraction was performed.

Protein extraction and electrophoretic mobility shift assay (EMSA)

A Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime; Shanghai) and quantified proteins from a BCA Protein Assay Kit (Beyotime; Shanghai) were used for extraction and concentration determination. Protocols followed the manufacturer's instructions. The procedure for EMSA was described in the instructions for a LightShift[®] Chemiluminescent EMSA Kit (Thermo Scientific; USA). In brief, a control Epstein-Barr nuclear antigen (EBNA) system included three reactions: specific binding reactions, competition reactions and negative reactions that contained no protein extract, while the test system included additional TFBS mutation reactions. The biotin end-labeled target DNA, unlabeled DNA and TFBS mutation DNA were amplified by PCR. The unlabeled DNA sequences were the same as the biotin-labeled sequences, and primers of the oligos for biotin-labeled target DNA and TFBS mutation DNA are listed in [Table S1](#). Next, 0.1 μ M biotin-labeled target DNA (2 μ l), 10x binding buffer (2 μ l), 1 μ g/ μ l poly (dI-dC) (1 μ l), 50% glycerol (1 μ l), 1% NP-40 (1 μ l) and 100 mM MgCl₂ (1 μ l) were in each reaction, and 10 μ M unlabeled DNA (4 μ l) was in a competition reaction while 10 μ M TFBS mutated DNA (4 μ l) was in a TFBS mutation reaction. All reactions contained 10 μ g of protein extract except the negative control. After incubation at room temperature for 30 min, 20 μ l of each binding sample was loaded onto a 6% polyacrylamide gel. A 0.45 μ m nylon membrane was used for electrophoretic transfer on ice with 0.5X TBE at 380 mA (\sim 100 V) for 30 min. Biotin-labeled DNA was detected by chemiluminescence after the membrane was blocked for 15 min and washed 5 times (5 min/wash).

Fluorescent image processing and analysis

The expression of GFP in microinjected zebrafish embryos was detected by a fluorescence microscope (Leica 205C; Germany) at 24 hpf, 48 hpf and 72 hpf, and expression in the injected group was compared with that in the noninjected group, while impurities on

the microscope lens shown as black dots. Positive embryos with the specific expression of GFP in heart tissue were maintained for a follow-up study. The different time points of observation of the transgenic zebrafish lines included 24 hpf, 48 hpf, 72 hpf, 96 hpf, 5 days postfertilization (dpf) and 10 dpf. The distribution of the fluorescent expression in the embryos of the stable transgenic zebrafish line crossed with *Tg* (*myl7:mCherry*) was observed by confocal microscopy (Leica TCS SP8 X; Germany). All images were adjusted by the professional software ImageJ and Adobe Illustrator CS6.

Statistical analysis

Mean values and standard errors were calculated using standard methods. All experiments were repeated at least 3 times. GraphPad Prism 6.0 was used for all statistical analyses. Student's t test was used for the statistical analysis between two groups. When comparing multiple experiments, a One-way ANOVA was used to test for homogeneity of variance. Bonferroni's test was used to correct for multiple comparisons based on confidence intervals and significance. A value of $p < 0.05$ was considered to be statistically significant.

RESULTS


Identification of a 183 bp ECR located 84 kb upstream of *tnni1b*

To investigate the functional enhancers of *tnni1b*, we performed a comparative analysis on the 219 kb zebrafish genomic region encompassing the *tnni1b* gene and the 100 kb regions upstream and downstream of *tnni1b*. In total, 16 ECRs were in the target genomic region (Fig. 2A). Information on these ECRs is listed in Table S2. According to the screening criteria, we found that one 183 bp ECR (location: *zv9*-chr6: 54883657-54883839, percent identity: 71.6%) was located at approximately 84 kb upstream of *tnni1b* (Fig. 2A). An overlapping alignment block is shown in Fig. 2B. After the injection of the enhancer DNA construct and *tol2* mRNA, the GFP expression driven by this 183 bp zebrafish DNA fragment was mainly detected in the heart (Figs. 3A–3C), and fewer and weaker GFP signals were detected outside of the heart, such as in the head or back (Fig. S1). The average ratios of heart-specific GFP expression embryos to total surviving embryos were 10/45 (22%) at 24 hpf, 15/41 (37%) at 48 hpf, and 15/39 (38%) at 72 hpf. The rate of embryos with GFP expression in the heart and other tissues at 48 hpf is shown in Fig. 3G. Notably, among the total embryos with GFP expression, more than 70% showed heart-specific fluorescent expression at different time points. We termed this ECR *tnni1b*-ECR183.

The core region, *tnni1b*-ECR183-d2, is only 87 bp

We performed deletion analysis to find the core region of *tnni1b*-ECR183 based on the TF binding affinity analysis described previously (Hallikas et al., 2006). As shown in Fig. 4, the results of PROMO analysis showed that approximately 112 putative binding conditions and TFs mostly bound to the nucleotide sequence 1 to 142, which was the potential core region of this 183 bp sequence. Combined with the 388 TFBSs sought by JASPAR, we found that 60% of TFBSs covered the range in the nucleotide sequence from 1 to 87, 26% from the nucleotide sequence 74 to 142 and only 20% from the nucleotide sequence 142 to 183. We then focused on the analysis of the nucleotide sequence 1 to 87 and

A



B

```

hg19  TGCCTTCTGCTCTCCACCCAGCTCCCTGGAGATGA---CCTGCTACGACAGCGATGATGCCA
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
danRer7 TGTCCTTTCCCTCTGC--AGTTGTCTGGAGAGCAGCGTCTGCTATGACAGCGATGAAACCA

hg19  ACCCACGCAGCGTGTCCAGCCTCTCCAACCGCTCGTCCCCTCTGTTCATGGCGCTATGGCCAG
      | | ||||| | ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
danRer7 ATGCTCGCAGCATCTCCAGCCTCTCCAACCGCTCGTCTCCTCTCTCCTGGCGCCACGGTCAG

hg19  TCCAGTCCGCGGCTGCAGGCTGGTGACGCGC---CCTCTGTGGGTGGGAGCTGCCGCTCGG
      ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
danRer7 TCCAGTCCCTCGTCTCCAAGCCGAGATGCTCCTTCTCTACCGGCAGCAGTATCTGTTCAG
  
```

Figure 2 Comparative analysis of the genomic loci of *tnni1b*. (A) ECR Browser and parameter set between zebrafish and human genomes around the 219 kb genome range encompassing the *tnni1b* gene and 100 kb regions upstream and downstream of *tnni1b*. Genes are shown in blue, and the 16 ECRs are shown in the red segment. (B) Overlapping alignment block: sequences of hg19-chr1:201687497-201687890 and zv9-chr6:54883657-54884033.

Full-size DOI: 10.7717/peerj.10289/fig-2

found that the putative TFs mainly bound to the nucleotide sequence 2 to 43. We therefore constructed three enhancer activity detection constructs that contained truncated enhancer DNA fragments *tnni1b*-ECR183-d1 (nucleotide sequence 74 to 142), *tnni1b*-ECR183-d2 (nucleotide sequence 1 to 87) and *tnni1b*-ECR183-d3 (nucleotide sequence 2 to 43) (Fig. 4). After comparing the rate of embryos with heart-specific GFP expression between the *tnni1b*-ECR183 and each truncated enhancer group at 48 hpf (Fig. 3H), we found that *tnni1b*-ECR183-d2 was also capable of driving the heart-specific expression of GFP ($p > 0.9999$). Images of embryos injected with *tnni1b*-ECR183-d2 at 24 hpf, 48 hpf and 72 hpf are shown in Figs. 3D–3F, and the corresponding videos are respectively shown in Videos S1, S2 and S3. Moreover, the average ratios of heart-specific GFP expression in total live embryos were 7/59 (12%) at 24 hpf, 18/48 (38%) at 48 hpf and 16/43 (37%) at 72 hpf. Similar to *tnni1b*-ECR183, among the total embryos with GFP expression, the percentage of embryos with heart-specific GFP expression driven by *tnni1b*-ECR183-d2 was over 70%. In addition, *tnni1b*-ECR183-d3 also drove GFP expression in some zebrafish embryos, but




Figure 3 GFP expression after the injection of zebrafish enhancers. Lateral views of zebrafish embryos with heart-specific GFP expression after injection with tol2 mRNA and tnni1b-ECR183 (A–C) or tnni1b-ECR183-d2 (D–F), scale bars = 100 μ m. The average ratios of heart-specific GFP expression embryos to the total surviving embryos were 10/45 (22%) at 24 hpf, 15/41 (37%) at 48 hpf, and 15/39 (38%) at 72 hpf in the tnni1b-ECR183 group and 7/59 (12%) at 24 hpf, 18/48 (38%) at 48 hpf and 16/43 (37%) at 72 hpf in the tnni1b-ECR183-d2 group. (G) Rate of embryos with GFP expression in different tissues at 48 hpf after injection with tnni1b-ECR183. (H) Rate of embryos with heart-specific GFP expression from transient injections of tnni1b-ECR183 and each truncated enhancer with tol2 transposase at 48 hpf. A *t*-test was used for statistical analyses between the two groups (G). One-way ANOVA was used to test for homogeneity of variance, and Bonferroni's test was used to correct for multiple comparisons (H). ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$, $n = 3$.

Full-size DOI: 10.7717/peerj.10289/fig-3

the fluorescence intensity was weaker and the ratio of heart-specific GFP expression was less than that of tnni1b-ECR183 ($p = 0.0005$) (Fig. 3H). These results suggest that the core region of tnni1b-ECR183 is tnni1b-ECR183-d2, which is 87 bp in size, and it also has the enhancer activity to drive the specific expression of GFP in the zebrafish heart.




Figure 4 Putative TFBS analysis of *tnni1b*-ECR183 by PROMO and the specific positions of truncated enhancer fragments including *tnni1b*-ECR183-d1, *tnni1b*-ECR183-d2, and *tnni1b*-ECR183-d3. TFBSs are displayed in fragments of different colors and numbers. The area division of the triangle represents the distribution density of TFBSs.

Full-size DOI: 10.7717/peerj.10289/fig-4

Tnni1b-ECR183-d2 drives the specific expression of GFP near the atrioventricular junction

In order to better clarify the spatial and temporal distribution of heart-specific fluorescent expression driven by *tnni1b*-ECR183-d2, we generated the transgenic line *Tg* (*tnni1b*-ECR183-d2: GFP) and observed the expression of GFP in offspring at different time points. We found that the heart-specific green fluorescence was detectable at 24 hpf, 48 hpf, 72 hpf, 96 hpf, 5 dpf and 10 dpf (Fig. 5). *Myf7* is a typical cardiac gene, and the fluorescence reporter gene that is driven by the promoter of *myf7* is often used to mark cardiomyocytes (Shi et al., 2017; Elworthy et al., 2019; Fricke et al., 2020). To better observe the specific position of fluorescent expression driven by *tnni1b*-ECR183-d2 in the heart, we then crossed *Tg* (*tnni1b*-ECR183-d2: GFP) with *Tg* (*myf7*: mCherry) to generate the transgenic line *Tg* (*tnni1b*-ECR183-d2: GFP; *myf7*: mCherry), and perform co-localization




Figure 5 The heart-specific GFP expression in the stable transgenic zebrafish line *Tg* (*tnni1b*-*ECR183-d2*: *GFP*). (A–E) Lateral views of zebrafish embryos with heart-specific GFP expression at 24 hpf, 48 hpf, 72 hpf, 96 hpf and 5 dpf. (F) Ventral view of zebrafish embryo with heart-specific GFP expression at 10 dpf. Scale bars = 100 μ m.

Full-size DOI: 10.7717/peerj.10289/fig-5

analysis by comparing the difference between the green and red fluorescence expressions. As shown in Figs. 6A–6F, both the green fluorescence driven by *tnni1b*-*ECR183-d2* and the red fluorescence driven by the promoter of cardiac gene *myl7* were detected in the heart, indicating that *tnni1b*-*ECR183-d2* is a cardiac enhancer. Zebrafish heart began to loop at 30 hpf, exhibited an obvious ‘s’-shape until 36 hpf, and gradually expanded to the recognizable atrium and ventricle chambers around 48 hpf (Kimmel *et al.*, 1995; Grant *et al.*, 2017). We used a confocal microscope to capture the heart images of zebrafish embryos at 48 hpf and 72 hpf to facilitate further comparisons and analyses. As shown in Figs. 6G–6L, in zebrafish embryos of *Tg* (*tnni1b*-*ECR183-d2*: *GFP*; *myl7*: *mCherry*), *GFP* driven by *tnni1b*-*ECR183-d2* is expressed in green fluorescence and *mCherry* driven by the promoter of cardiomyocyte-specific gene *myl7* is expressed in red fluorescence. The overlapping yellow part represents the cardiomyocytes expressing both *GFP* and *mCherry*, which are mostly in the atrium and ventricle boundary. Taken together, these results show that *tnni1b*-*ECR183-d2* is a heart-specific enhancer, and the *GFP* expression driven by this enhancer is around the atrioventricular junction.

Analysis of the enhancer activity of *tnni1b*-*ECR183-d2* by a luciferase assay

We also performed functional analysis of *tnni1b*-*ECR183* and *tnni1b*-*ECR183-d2* in vitro. We generated the enhancer activity detection constructs and transfected them into HEK293 cells and HL1 cells. As shown in Figs. 7A–7B, higher luciferase activity was detected in the *tnni1b*-*ECR183* group (in HEK293 cells: $p < 0.0001$; in HL1 cells: $p = 0.0199$) and *tnni1b*-*ECR183-d2* group (in HEK293 cells: $p < 0.0001$; in HL1 cells: $p = 0.0075$) than in the pGL3-E1b group. Combined with the *GFP* expression in the zebrafish heart driven by




Figure 6 Heart-specific GFP expression in zebrafish embryos of *Tg* (*tnni1b*-*ECR183*-*d2*: GFP; *myl7*: mCherry). (A–F) Lateral views of zebrafish embryos with GFP expression driven by *tnni1b*-*ECR183*-*d2* (A–C) and those with mCherry expression driven by the promoter of *myl7* (D–F). (G–L) Confocal images of ventral views of these embryos with GFP expressed in green (G, J), mCherry expressed in red (H, K) and the overlapping part expressed in yellow (I, L). White line, heart outline; A, atrium; V, ventricle. Scale bars = 100 μm.

Full-size DOI: 10.7717/peerj.10289/fig-6




Figure 7 Identification of the enhancer activity and analysis of putative TFBSs. Enhancer activity identification of *tnni1b*-ECR183 and *tnni1b*-ECR183-d2 by the luciferase assay in the HEK293 (A) and HL1 cell lines (B). (C) Putative TFBS positions and mutations. Analysis of the enhancer activity of *tnni1b*-ECR183-d2 after putative TFs were overexpressed (D) or after *NKX2.5* (E) and *JUN* (F) binding sites were mutated. One-way ANOVA was used to test for homogeneity of variance, and Bonferroni's test was used to correct for multiple comparisons (A, B, D). A *t*-test was performed for statistical analyses between two groups (E, F). * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$, $n = 3$.

Full-size DOI: [10.7717/peerj.10289/fig-7](https://doi.org/10.7717/peerj.10289/fig-7)

tnni1b-ECR183-d2, these results of in vivo and in vitro verification showed that this 87 bp ECR was a functional heart-specific enhancer.

Tnni1b-ECR183-d2 has positive correlations with NKX2.5 or JUN

Among the putative TFs, four cardiac TFs including NKX2.5, GATA4, ETS1 and JUN were closely related to heart development according to previously published studies. After performing the TF overexpression analysis, we found that the enhancer activity of tnni1b-ECR183-d2 increased significantly when NKX2.5 ($p = 0.0006$) or JUN ($p < 0.0001$) was overexpressed (Fig. 7D). According to the website tools and mutation principles introduced in the Methods section, we then performed further experiments on TFBS mutations (Fig. 7C). The enhancer activity was significantly decreased when the putative binding sequence of NKX2.5 was mutated from ATCTCCG to ATCGCCG ($p < 0.0001$) (Fig. 7E); those of JUN were mutated from TGACAGA and GACTGAC to TGATAGA and GACGGAC, respectively ($p = 0.0018$) (Fig. 7F). In addition, no DNA-protein interactions between these TFs and tnni1b-ECR183-d2 were detected by autoradiography in the EMSA experiment (Fig. S2). These results suggest that TFs, including NKX2.5 and JUN, might have a positive indirect effect on the enhancer function of tnni1b-ECR183-d2.

Functional analysis of human enhancers

To analyze the conservation between zebrafish and human enhancers, we aligned tnni1b-ECR183 and tnni1b-ECR183-d2 to human DNA sequences located 288.6 kb upstream of TNNI1, which were termed tnni1b-ECR183-h179 (location: hg19-chr1: 201687497-201687675) and tnni1b-ECR183-h84 (location: hg19-chr1: 201687592-201687675), respectively. After functionally verifying these human enhancer regions, we found that zebrafish embryos injected with tol2 mRNA and tnni1b-ECR183-h179 showed GFP expression in skeletal muscles alone or in the heart, skeletal and craniofacial muscles (Figs. 8A–8F). The rates of embryos with GFP expression in different tissues suggested that tnni1b-ECR183-h179 dominantly drove GFP expression in the skeletal muscles, the heart, or both (Fig. 8J). Interestingly, those embryos injected with tnni1b-ECR183-h84 showed GFP expression mainly in the skeletal muscles (Figs. 8G–8I). As shown in Fig. 8K, luciferase expression was increased by tnni1b-ECR183-h84 ($p = 0.0001$), while expression driven by tnni1b-ECR183-h179 did not show a significant increase. To determine whether the same TFBSs tested in the zebrafish enhancer regions were conserved, we further analyzed the enhancer activity of tnni1b-ECR183-h179 and tnni1b-ECR183-h84 after putative TFs were overexpressed. Figure 8L shows that the luciferase expression level was significantly increased by tnni1b-ECR183-h179 when NKX2.5 ($p < 0.0001$), JUN ($p < 0.0001$) or ETS1 ($p < 0.0001$) was overexpressed. However, the enhancer activity of tnni1b-ECR183-h84 decreased when NKX2.5 ($p = 0.0028$), ETS1 ($p = 0.0001$) or GATA4 ($p < 0.0001$) was overexpressed (Fig. 8M), which suggested a weak correlation between this enhancer and the heart. The above results indicate that the human enhancer tnni1b-ECR183-h179 is related to the heart and skeletal muscles while tnni1b-ECR183-h84 is a skeletal muscle-specific enhancer.

DISCUSSION

Currently, etiology analyses of CHDs focus mostly on the variants in the coding regions of several typical heart-related genes (McCulley & Black, 2012). Interestingly though, the




Figure 8 Functional analysis of human enhancers. (A–F) Lateral views of zebrafish embryos with GFP expression after injection with tol2 mRNA and ttni1b-ECR183-h179. (G–I) Lateral views of zebrafish embryos with GFP expression after injection with tol2 mRNA and ttni1b-ECR183-h84. The arrowheads indicate GFP expression in the skeletal muscles (A, B, D, F, G, H, I), craniofacial muscles (B, C, D, F) and hearts (E, F), scale bars = 100 μ m. Rate of embryos with GFP expression in different tissues after injection with ttni1b-ECR183-h179 (J). Enhancer activity identification of ttni1b-ECR183-h179 and ttni1b-ECR183-h84 in HEK293 cell lines (K). Analysis of the enhancer activity of ttni1b-ECR183-h179 (L) and ttni1b-ECR183-h84 (M) after putative TFs were overexpressed. One-way ANOVA was used to test for homogeneity of variance, and Bonferroni's test was used to correct for multiple comparisons. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$, $n = 3$.

Full-size DOI: 10.7717/peerj.10289/fig-8

findings of published studies that used targeted gene panels or exome sequencing implicate that approximately 90% of sporadic CHD patients do not carry mutations in exon regions (Blue *et al.*, 2017), indicating that other causes including unknown pathogenic genes and variations in regulatory regions, should not be ignored. Indeed, mutations in the regulatory regions of cardiac genes can also cause several heart defects (Pang *et al.*, 2012; Smemo *et al.*, 2012; Wu *et al.*, 2012; Gu *et al.*, 2017), such as the mutation rs118026695 within the promoter of NKX2.5 and the homozygous mutation in an enhancer, which is located approximately 90 kb downstream of TBX5. In this study, we found that an enhancer located 84 kb upstream of *tnni1b* was capable of mediating specific GFP expression in zebrafish hearts. Notably, this heart-specific enhancer in this study was only 87 bp in size, and the enhancer in our previous study was also small (42 bp) (Wang *et al.*, 2019). Taken together, we think that small enhancers that are remote from cardiac genes are still functional; thus, future studies are needed to explore the specific function of these enhancers on target genes and their roles in the development or pathophysiology of the heart.

Fluorescently-labeled transgenic zebrafish lines, which are mediated by tissue-specific regulatory elements, are useful in pathophysiology studies (Da Silva Lopes *et al.*, 2011; Shi *et al.*, 2017). For instance, the dynamics of centrosomes in radial glia neural progenitors were observed by performing time-lapse imaging on the zebrafish brain, where the nucleus was labeled by GFP and the plasma membrane was labeled by tdTomato (Yu *et al.*, 2016). In this study, the transgenic zebrafish line *Tg* (*tnni1b*-ECR183-d2: GFP) was used to track the heart-specific fluorescent expression in real-time during zebrafish development. This result suggests that the GFP expression mediated by *tnni1b*-ECR183-d2 can be used as a heart-specific marker, and such a transgenic zebrafish line is expected to be useful for cardiovascular research.

To identify the TFs that interacted with *tnni1b*-ECR183-d2, we performed TFBS analysis using JASPAR and PROMO and selected four TFs associated with heart development. Combined with the TF overexpression and TFBS mutation experimental results, we found that NKX2.5 or JUN was necessary for enhancer activation of *tnni1b*-ECR183-d2. However, the EMSA results did not show direct interactions between them. One of the explanations of this result is that the specific binding reactions between TFs and enhancers are not strong enough to be detected. Moreover, given that the gene regulatory network is complex and that TFs could collaborate with each other (Csumita *et al.*, 2020; Theeuwes *et al.*, 2020), indirect interactions might exist between the above TFs and enhancers in our study.

In addition, we compared the heart-specific fluorescent expression in our study with the gene expression pattern of in situ hybridization on ZFIN (<http://zfin.org/>) to investigate the target genes that might be regulated by *tnni1b*-ECR183-d2. Researchers have found that *tnni1b* is expressed in the heart rudiment and heart tube of zebrafish at 24 hpf and 48 hpf respectively, and becomes stable in the heart after 60 hpf (<http://zfin.org/ZDB-GENE-041212-37/expression>). This expression pattern is consistent with the spatiotemporal expression of green fluorescence driven by *tnni1b*-ECR183-d2. In addition, it was reported that *tnni1b*^{-/-} zebrafish showed developmental defects of the endocardial ring at the atrioventricular junction (Cai *et al.*, 2019), and the confocal images

in our study showed the strong expression of green fluorescence near the atrioventricular junction. This evidence indicates that *tnni1b* might be the target gene regulated by *tnni1b*-ECR183-d2.

To analyze the conservation between zebrafish and human enhancers, we functionally verified the human enhancers *tnni1b*-ECR183-h179 and *tnni1b*-ECR183-h84, which were aligned from *tnni1b*-ECR183 and *tnni1b*-ECR183-d2. In the human genome, TNNI1 encodes the slow skeletal muscle isoform of TnI (ssTnI), while TNNI3 encodes the cardiac isoform of TnI (cTnI). Previous studies have demonstrated that the TnI isoforms are functionally conservative and ssTnI is expressed in both skeletal muscles and hearts in fetuses (Saggin *et al.*, 1989; Sasse *et al.*, 1993). Similarly, in this study, the GFP expression in zebrafish embryos observed after injection showed that *tnni1b*-ECR183-h179, which is located at 288.6 kb upstream of TNNI1, is related to the heart and skeletal muscles. However, the luciferase assay did not identify obvious enhancer activity of *tnni1b*-ECR183-h179. Considering the complex gene regulatory network and the collaboration between TFs (Csumita *et al.*, 2020), *tnni1b*-ECR183-h179 might bind to repressive TFs to decrease the expression of luciferase in this study. The truncated fragment *tnni1b*-ECR183-h84 showed skeletal muscle-specific enhancer activity. Combined with the findings that the zebrafish DNA fragments in this study were heart-specific enhancers, we hypothesize that the zebrafish and human enhancers in this study target different tissues.

Here, a small (87 bp) heart-specific enhancer of zebrafish that lies 84 kb upstream of *tnni1b* was identified. In the future, the spatiotemporal activity of the new enhancer reported in this study should be thoroughly studied in mice or chickens. Further research is needed to explore the specific function of this enhancer on *tnni1b*, such as the specific expression site of *tnni1b* driven by this enhancer, and the role of the enhancer in heart development or tissue homeostasis.

CONCLUSIONS

We identified an 87 bp heart-specific enhancer, *tnni1b*-ECR183-d2, which is located 84 kb upstream of the heart development-related gene *tnni1b*. The enhancer activity is positively correlated with NKX2.5 or JUN. Although the zebrafish and human enhancers in this study target different tissues, this 87 bp zebrafish enhancer is capable of dominantly driving the specific GFP expression near the atrioventricular junction of the heart. Therefore, the fluorescent label of zebrafish lines mediated by this small but functional heart-specific enhancer is expected to be helpful for cardiovascular research. Further studies are needed to explore the specific regulation of *tnni1b*-ECR183-d2 on *tnni1b*.

ACKNOWLEDGEMENTS

We are grateful to Jia Lin and Yinglan Zhang for their technical support, Professor G. Huang for providing the ETS1 overexpression construct and Professor Q. Jiang for providing transgenic zebrafish line *Tg* (*myl7*: mCherry).

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was supported by grants from the National Natural Science Foundations of China (grant No. 81771632) and the National Key Research and Development Program (grant No. 2016YFC1000500) to Qiang Li; by the National Natural Science Foundations of China (grant No. 81470442, 81741081, 81873481 and 81170147), 973 Program (grant No. 2013CB945401) to Yonghao Gui; and by the Shanghai Key Laboratory of Birth Defects (grant No. 13DZ2260600). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:

National Natural Science Foundations of China: 81771632, 81470442, 81741081, 81873481, 81170147.

National Key Research and Development Program: 2016YFC1000500.

973 Program: 2013CB945401.

Shanghai Key Laboratory of Birth Defects: 13DZ2260600.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Yawen Zhang and Feng Wang performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
- Fang Wu performed the experiments, prepared figures and/or tables, and approved the final draft.
- Youhua Wang, Xu Wang, Yonghao Gui and Qiang Li conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

Animal Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The Institutional Animal Care and Use Committee of Children's Hospital of Fudan University approved this research (approval number: EK(2018)73).

Data Availability

The following information was supplied regarding data availability:

The raw data are available in the [Supplementary Files](#).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.10289#supplemental-information>.

REFERENCES

- Abbasi AA, Papparidis Z, Malik S, Bangs F, Schmidt A, Koch S, Lopez-Rios J, Grzeschik KH. 2010. Human intronic enhancers control distinct sub-domains of Gli3 expression during mouse CNS and limb development. *BMC Developmental Biology* 10:44 DOI 10.1186/1471-213X-10-44.
- Anwar S, Minhas R, Ali S, Lambert N, Kawakami Y, Elgar G, Azam SS, Abbasi AA. 2015. Identification and functional characterization of novel transcriptional enhancers involved in regulating human GLI3 expression during early development. *Development, Growth & Differentiation* 57(8):570–580 DOI 10.1111/dgd.12239.
- Arkipova V, Wendik B, Devos N, Ek O, Peers B, Meyer D. 2012. Characterization and regulation of the hb9/mnx1 beta-cell progenitor specific enhancer in zebrafish. *Developmental Biology* 365(1):290–302 DOI 10.1016/j.ydbio.2012.03.001.
- Blue GM, Kirk EP, Giannoulatou E, Sholler GF, Dunwoodie SL, Harvey RP, Winlaw DS. 2017. Advances in the genetics of congenital heart disease: a clinician's guide. *Journal of the American College of Cardiology* 69(7):859–870 DOI 10.1016/j.jacc.2016.11.060.
- Cai C, Sang C, Du J, Jia H, Tu J, Wan Q, Bao B, Xie S, Huang Y, Li A, Li J, Yang K, Wang S, Lu Q. 2019. Knockout of tnni1b in zebrafish causes defects in atrioventricular valve development via the inhibition of the myocardial wnt signaling pathway. *Federation of American Societies for Experimental Biology Journal* 33(1):696–710 DOI 10.1096/fj.201800481RR.
- Chan S, Shen D, Sang Y, Wang S, Wang Y, Chen C, Gao B, Song C. 2019. Development of enhancer-trapping and -detection vectors mediated by the Tol2 transposon in zebrafish. *PeerJ* 7:e6862 DOI 10.7717/peerj.6862.
- Charité J, McFadden DG, Merlo G, Levi G, Clouthier DE, Yanagisawa M, Richardson JA, Olson EN. 2001. Role of Dlx6 in regulation of an endothelin-1-dependent, dHAND branchial arch enhancer. *Genes & Development* 15(22):3039–3049 DOI 10.1101/gad.931701.
- Csumita M, Csermely A, Horvath A, Nagy G, Monori F, Göczi L, Orbea HA, Reith W, Széles L. 2020. Specific enhancer selection by IRF3, IRF5 and IRF9 is determined by ISRE half-sites, 5' and 3' flanking bases, collaborating transcription factors and the chromatin environment in a combinatorial fashion. *Nucleic Acids Research* 48(2):589–604 DOI 10.1093/nar/gkz1112.
- Da Silva Lopes K, Pietas A, Radke MH, Gotthardt M. 2011. Titin visualization in real time reveals an unexpected level of mobility within and between sarcomeres. *The Journal of Cell Biology* 193(4):785–798 DOI 10.1083/jcb.201010099.
- Delporte FM, Pasque V, Devos N, Manfroid I, Voz ML, Motte P, Biemar F, Martial JA, Peers B. 2008. Expression of zebrafish pax6b in pancreas is regulated by two enhancers containing highly conserved cis-elements bound by PDX1, PBX and PREP factors. *BMC Developmental Biology* 8:53 DOI 10.1186/1471-213X-8-53.

- Elworthy S, Savage AM, Wilkinson RN, Malicki JJ, Chico TJA. 2019. The role of endothelial cilia in postembryonic vascular development. *Developmental Dynamics* 248(6):410–425 DOI 10.1002/dvdy.40.
- Fahed AC, Gelb BD, Seidman JG, Seidman CE. 2013. Genetics of congenital heart disease: the glass half empty. *Circulation Research* 112(4):707–720 DOI 10.1161/CIRCRESAHA.112.300853.
- Fricke T, Smalakyte D, Lapinski M, Pateria A, Weige C, Pastor M, Kolano A, Winata C, Siksnys V, Tamulaitis G, Bochtler M. 2020. Targeted RNA knockdown by a Type III CRISPR-cas complex in Zebrafish. *The CRISPR Journal* 3(4):299–313 DOI 10.1089/crispr.2020.0032.
- Goszczyński B, Captan VV, Danielson AM, Lancaster BR, McGhee JD. 2016. A 44 bp intestine-specific hermaphrodite-specific enhancer from the *C. elegans* vit-2 vitellogenin gene is directly regulated by ELT-2, MAB-3, FKH-9 and DAF-16 and indirectly regulated by the germline, by *daf-2/insulin* signaling and by the TGF-beta/Sma/Mab pathway. *Developmental Biology* 413(1):112–127 DOI 10.1016/j.ydbio.2016.02.031.
- Grant MG, Patterson VL, Grimes DT, Burdine RD. 2017. Modeling syndromic congenital heart defects in zebrafish. *Current Topics in Developmental Biology* 124:1–40 DOI 10.1016/bs.ctdb.2016.11.010.
- Gu R, Xu J, Lin Y, Sheng W, Ma D, Ma X, Huang G. 2017. The role of histone modification and a regulatory single-nucleotide polymorphism (rs2071166) in the *Cx43* promoter in patients with T.O.F. *Scientific Reports* 7(1):10435 DOI 10.1038/s41598-017-10756-6.
- Hallikas O, Palin K, Sinjushina N, Rautiainen R, Partanen J, Ukkonen E, Taipale J. 2006. Genome-wide prediction of mammalian enhancers based on analysis of transcription-factor binding affinity. *Cell* 124(1):47–59 DOI 10.1016/j.cell.2005.10.042.
- Hernández-Vega A, Minguillón C. 2011. The *Prx1* limb enhancers: targeted gene expression in developing zebrafish pectoral fins. *Developmental Dynamics* 240(8):1977–1988 DOI 10.1002/dvdy.22678.
- Homsy J, Zaidi S, Shen Y, Ware JS, Samocha KE, Karczewski KJ, DePalma SR, McKean D, Wakimoto H, Gorham J, Jin SC, Deanfield J, Giardini A, Porter GAJR, Kim R, Bilguvar K, López-Giráldez F, Tikhonova I, Mane S, Romano-Adesman A, Qi H, Vardarajan B, Ma L, Daly M, Roberts AE, Russell MW, Mital S, Newburger JW, Gaynor JW, Breitbart RE, Iossifov I, Ronemus M, Sanders SJ, Kaltman JR, Seidman JG, Brueckner M, Gelb BD, Goldmuntz E, Lifton RP, Seidman CE, Chung WK. 2015. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. *Science* 350(6265):1262–1266 DOI 10.1126/science.aac9396.
- Ikle JM, Artinger KB, Clouthier DE. 2012. Identification and characterization of the zebrafish pharyngeal arch-specific enhancer for the basic helix-loop-helix transcription factor *Hand2*. *Developmental Biology* 368(1):118–126 DOI 10.1016/j.ydbio.2012.05.003.

- Kim Y, Park E, Park S. 2015.** Identification of the 187 bp EphA7 genomic DNA as the dorsal midline-specific enhancer of the diencephalon and mesencephalon. *Molecules and Cells* **38**(11):1007–1012 DOI [10.14348/molcells.2015.0221](https://doi.org/10.14348/molcells.2015.0221).
- Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. 1995.** Stages of embryonic development of the zebrafish. *Developmental Dynamics* **203**(3):253–310 DOI [10.1002/aja.1002030302](https://doi.org/10.1002/aja.1002030302).
- Lettice LA, Heaney SJ, Purdie LA, Li L, De Beer P, Oostra BA, Goode D, Elgar G, Hill RE, De Graaff E. 2003.** A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly. *Human Molecular Genetics* **12**(14):1725–1735 DOI [10.1093/hmg/ddg180](https://doi.org/10.1093/hmg/ddg180).
- Li Q, Ritter D, Yang N, Dong Z, Li H, Chuang JH, Guo S. 2010.** A systematic approach to identify functional motifs within vertebrate developmental enhancers. *Developmental Biology* **337**(2):484–495 DOI [10.1016/j.ydbio.2009.10.019](https://doi.org/10.1016/j.ydbio.2009.10.019).
- McCulley DJ, Black BL. 2012.** Transcription factor pathways and congenital heart disease. *Current Topics in Developmental Biology* **100**:253–277 DOI [10.1016/B978-0-12-387786-4.00008-7](https://doi.org/10.1016/B978-0-12-387786-4.00008-7).
- Ovcharenko I, Nobrega MA, Loots GG, Stubbs L. 2004.** ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes. *Nucleic Acids Research* **32**(Web Server issue):W280–W286 DOI [10.1093/nar/gkh355](https://doi.org/10.1093/nar/gkh355).
- Pang S, Shan J, Qiao Y, Ma L, Qin X, Wanyan H, Xing Q, Wu G, Yan B. 2012.** Genetic and functional analysis of the NKX2-5 gene promoter in patients with ventricular septal defects. *Pediatric Cardiology* **33**(8):1355–1361 DOI [10.1007/s00246-012-0346-0](https://doi.org/10.1007/s00246-012-0346-0).
- Posner M, Murray KL, McDonald MS, Eighinger H, Andrew B, Drossman A, Haley Z, Nussbaum J, David LL, Lampi KJ. 2017.** The zebrafish as a model system for analyzing mammalian and native α -crystallin promoter function. *PeerJ* **5**:e4093 DOI [10.7717/peerj.4093](https://doi.org/10.7717/peerj.4093).
- Postma AV, Bezzina CR, Christoffels VM. 2016.** Genetics of congenital heart disease: the contribution of the noncoding regulatory genome. *Journal of Human Genetics* **61**(1):13–19 DOI [10.1038/jhg.2015.98](https://doi.org/10.1038/jhg.2015.98).
- Saggin L, Gorza L, Ausoni S, Schiaffino S. 1989.** Troponin I switching in the developing heart. *Journal of Biological Chemistry* **264**(27):16299–16302.
- Sandelin A, Alkema W, Engström P, Wasserman WW, Lenhard B. 2004.** JASPAR: an open-access database for eukaryotic transcription factor binding profiles. *Nucleic Acids Research* **32**(Database issue):D91–D94 DOI [10.1093/nar/gkh012](https://doi.org/10.1093/nar/gkh012).
- Sasse S, Brand N, Kyprianou P, Dhoot G, Wade R, Arai M, Periasamy M, Yacoub M, Barton P. 1993.** Troponin I gene expression during human cardiac development and in end-stage heart failure. *Circulation Research* **72**(5):932–938 DOI [10.1161/01.res.72.5.932](https://doi.org/10.1161/01.res.72.5.932).
- Sheng JJ, Jin JP. 2016.** TNNI1, TNNI2 and TNNI3: evolution, regulation, and protein structure–function relationships. *Gene* **576**(1Pt3):385–394 DOI [10.1016/j.gene.2015.10.052](https://doi.org/10.1016/j.gene.2015.10.052).
- Shi X, Verma S, Yun J, Brand-Arzamendi K, Singh KK, Liu X, Garg A, Quan A, Wen XY. 2017.** Effect of empagliflozin on cardiac biomarkers in a zebrafish model of

- heart failure: clues to the EMPA-REG OUTCOME trial?. *Molecular and Cellular Biochemistry* **433**(1–2):97–102 DOI [10.1007/s11010-017-3018-9](https://doi.org/10.1007/s11010-017-3018-9).
- Shih YH, Zhang Y, Ding Y, Ross CA, Li H, Olson TM, Xu X. 2015.** Cardiac transcriptome and dilated cardiomyopathy genes in zebrafish. *Circulation. Cardiovascular Genetics* **8**(2):261–269 DOI [10.1161/CIRCGENETICS.114.000702](https://doi.org/10.1161/CIRCGENETICS.114.000702).
- Smemo S, Campos LC, Moskowitz IP, Krieger JE, Pereira AC, Nobrega MA. 2012.** Regulatory variation in a TBX5 enhancer leads to isolated congenital heart disease. *Human Molecular Genetics* **21**(14):3255–3263 DOI [10.1093/hmg/dds165](https://doi.org/10.1093/hmg/dds165).
- Suarez-Bregua P, Chien CJ, Megias M, Du S, Rotllant J. 2017.** Promoter architecture and transcriptional regulation of musculoskeletal embryonic nuclear protein 1b (mustn1b) gene in zebrafish. *Developmental Dynamics* **246**(12):992–1000 DOI [10.1002/dvdy.24591](https://doi.org/10.1002/dvdy.24591).
- Sun L, Chen F, Peng G. 2015.** Conserved noncoding sequences regulate lhx5 expression in the zebrafish forebrain. *PLOS ONE* **10**(7):e0132525 DOI [10.1371/journal.pone.0132525](https://doi.org/10.1371/journal.pone.0132525).
- Taminato T, Yokota D, Araki S, Ovara H, Yamasu K, Kawamura A. 2016.** Enhancer activity-based identification of functional enhancers using zebrafish embryos. *Genomics* **108**(2):102–107 DOI [10.1016/j.ygeno.2016.05.005](https://doi.org/10.1016/j.ygeno.2016.05.005).
- Theeuwes WF, Gosker HR, Schols AMWJ, Langen RCJ, Remels AHV. 2020.** Regulation of PGC-1 α expression by a GSK-3 β -TFEB signaling axis in skeletal muscle. *Biochimica et Biophysica Acta. Molecular Cell Research* **1867**(2):Article 118610 DOI [10.1016/j.bbamcr.2019.118610](https://doi.org/10.1016/j.bbamcr.2019.118610).
- Van der Bom T, Bouma BJ, Meijboom FJ, Zwinderman AH, Mulder BJ. 2012.** The prevalence of adult congenital heart disease, results from a systematic review and evidence based calculation. *American Heart Journal* **164**(4):568–575 DOI [10.1016/j.ahj.2012.07.023](https://doi.org/10.1016/j.ahj.2012.07.023).
- Waardenberg AJ, Ramialison M, Bouveret R, Harvey RP. 2014.** Genetic networks governing heart development. *Cold Spring Harbor Perspectives in Medicine* **4**(11):a013839 DOI [10.1101/cshperspect.a013839](https://doi.org/10.1101/cshperspect.a013839).
- Wang F, Yang Q, Wu F, Zhang Y, Sun S, Wang X, Gui Y, Li Q. 2019.** Identification of a 42-bp heart-specific enhancer of the notch1b gene in zebrafish embryos. *Developmental Dynamics* **248**(6):426–436 DOI [10.1002/dvdy.31](https://doi.org/10.1002/dvdy.31).
- Wu G, Shan J, Pang S, Wei X, Zhang H, Yan B. 2012.** Genetic analysis of the promoter region of the GATA4 gene in patients with ventricular septal defects. *Translational Research* **159**(5):376–382 DOI [10.1016/j.trsl.2011.10.012](https://doi.org/10.1016/j.trsl.2011.10.012).
- Yu D, Dong Z, Gustafson WC, Ruiz-González R, Signor L, Marzocca F, Borel F, Klassen MP, Makhijani K, Royant A, Jan YN, Weiss WA, Guo S, Shu X. 2016.** Rational design of a monomeric and photostable far-red fluorescent protein for fluorescence imaging in vivo. *Protein Science* **25**(2):308–315 DOI [10.1002/pro.2843](https://doi.org/10.1002/pro.2843).
- Zhang H, Liu L, Tian J. 2019.** Molecular mechanisms of congenital heart disease in down syndrome. *Genes & Diseases* **6**(4):372–377 DOI [10.1016/j.gendis.2019.06.007](https://doi.org/10.1016/j.gendis.2019.06.007).